Next Article in Journal
Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine
Previous Article in Journal
Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 12
Issue 7
10.3390/vaccines12070765
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of the Effect of Influenza Vaccine on the Development of Symptoms in SARS-CoV-2 Infection and Outcome in Patients Hospitalized due to COVID-19

by
Jose Roberto Gutierrez-Camacho
1,
Lorena Avila-Carrasco
1,*,
Araceli Gamón-Madrid
1,
Jose Ramon Muñoz-Torres
1,
Alberto Murillo-Ruiz-Esparza
2,
Idalia Garza-Veloz
1,
Perla M. Trejo-Ortiz
1,
Fabiana E. Mollinedo-Montaño
1,
Roxana Araujo-Espino
1,
Iram P. Rodriguez-Sanchez
3,
Ivan Delgado-Enciso
4 and
Margarita L. Martinez-Fierro
1,*
1
Doctorado en Ciencias con Orientación en Medicina Molecular, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Zacatecas 98160, Mexico
2
Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Zacatecas, Zacatecas 98000, Mexico
3
Laboratorio de Fisiologia Molecular y Estructural, Facultad de Ciencias Biologicas, Universidad Autonoma de Nuevo Leon, San Nicolas de Los Garza 66450, Mexico
4
Department of Molecular Medicine, School of Medicine, Cancerology State Institute, IMSS-Bienestar, University of Colima, Colima 28040, Mexico
*
Authors to whom correspondence should be addressed.
Vaccines 2024, 12(7), 765; https://doi.org/10.3390/vaccines12070765
Submission received: 11 June 2024 / Revised: 1 July 2024 / Accepted: 10 July 2024 / Published: 12 July 2024
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: COVID-19 is an infectious disease caused by SARS-CoV-2. It is unclear whether influenza vaccination reduces the severity of disease symptoms. Previous studies have suggested a beneficial effect of influenza vaccination on the severity of COVID-19. The aim of this study was to evaluate the possible protective effect of the influenza vaccine on the occurrence of SARS-CoV-2 infection symptoms and prognosis in patients hospitalized with COVID-19. Methods: This was a retrospective cohort study of patients who tested positive for SARS-CoV-2, identified by quantitative real-time polymerase chain reaction. Chi-square tests, Kaplan–Meier analysis, and multivariate analysis were performed to assess the association between influenza vaccination and the presence of symptoms in hospitalized patients with COVID-19 and their outcome. Results: In this study, 1712 patients received positive laboratory tests for SARS-CoV-2; influenza vaccination was a protective factor against the presence of characteristic COVID-19 symptoms such as polypnea, anosmia, dysgeusia, and fever (p < 0.001). Influenza-vaccinated patients had fewer days of hospitalization (p = 0.029). Conclusions: The findings of this study support that influenza vaccination is associated with a decrease in the number of symptoms in patients hospitalized due to COVID-19, with fewer days of hospitalization, but not with the outcome of disease.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the 2019 coronavirus disease (COVID-19) pandemic, leading to high morbidity and mortality rates worldwide [1,2]. So far, it has resulted in 770,875,433 cases of infection and 6,959,316 deaths, with significant global health and economic consequences [3].
On the other hand, seasonal influenza occurs annually from fall through spring, and it is usually caused by influenza A or B viruses. This infection has been associated with an increase in mortality and morbidity if there is SARS-CoV-2 co-infection [4,5,6,7]. Annual influenza vaccination is recommended by the World Health Organization (WHO) to prevent infections and severe complications, especially in high-risk groups such as pregnant women and older adults [8,9].
Due to the similar transmission mechanisms, researchers have looked at the relationship between SARS-CoV-2 infection and influenza immunity [10,11,12]. At present, there seems to be no compelling evidence of a negative impact of influenza vaccination on COVID-19 patients [13]. While some authors have shown that the influenza vaccine is not linked to incidence [14,15], severity [15,16], and mortality [15,17] of COVID-19, others have found some associations [18,19,20].
The fact that the use of influenza vaccines is widespread points to the need to clarify whether these vaccines may affect the outcome of SARS-CoV-2 infections. Actually, certain vaccines have protective effects on innate immunity, a process termed trained immunity (Figure 1); therefore, a beneficial effect of influenza vaccination on susceptibility to COVID-19 is possible [15,21,22,23].
The clinical features of COVID-19 are broad, and its severity ranges from mild symptoms to acute respiratory distress syndrome and death [24,25,26,27,28]. Pre-existing liver, cerebrovascular, renal, and gastrointestinal diseases, hypertension, type 2 diabetes mellitus (T2DM), and chronic obstructive pulmonary disease (COPD) increase susceptibility to SARS-CoV-2 infection, and are associated with increased risk of mortality [1,29].
It is of utmost importance to know that patients with pre-existing cardiovascular risk factors have a high rate of probability of developing severe disease as a consequence of cardiovascular complications of COVID-19 [30,31,32,33,34].
Humanity finds itself in a time of SARS-CoV-2 disease (COVID-19), which places an additional burden on healthcare systems, and creates the potential for co-infection of SARS-CoV-2 and influenza [35,36,37,38].
It has been suggested that receipt of influenza vaccination results in significant protection against most influenza viruses [11]. These are of greatest concern in the elderly and in patients with pre-existing medical conditions which could cause them to experience increased mortality and morbidity with influenza infection [39], in addition to being at increased risk of severe COVID-19 infection [1,29]. Influenza has already been reported to be associated with an increased risk of aortic dissection [40], myocarditis [41], myocardial infarction, stroke, and death in persons with cardiovascular disease [42,43,44]; it has also already been demonstrated that the administration of influenza vaccine reduces the risk of major adverse cardiovascular events in this population [45,46,47,48]. Therefore, year-to-year vaccination against influenza has been identified as an outstanding intervention to reduce the risk of cardiovascular events in patients with atherosclerotic or coronary vascular disease [49]. The increased risk of cardiovascular complications due to COVID-19 in these patients, in concert with the possible protective effect it generates against COVID-19, further supports the importance of influenza vaccination in this population [30,31,32,33].
The potential protection of influenza vaccination against the severity of SARS-CoV-2 infection, attributed to the induction of cross-neutralizing antibodies and T-cells [10,17,50,51], becomes relevant with the onset of the influenza season. In the light of the aforementioned, this study aimed at assessing the potential protective effect of influenza vaccine on the occurrence of SARS-CoV-2 infection symptomology, and on the outcome of patients hospitalized due to COVID-19.

2. Materials and Methods

2.1. Study Design

This cross-sectional study included hospitalized adult patients with a confirmed diagnosis of COVID-19 registered at Hospital General de Zacatecas Luz González Cosío (Zacatecas, Mexico) between 10 January 2020 and 31 December 2020. This study was revised and approved by the Ethics and Research Committee at the Zacatecas General Hospital Luz González Cosío (ID 02023/2019).
Study population: Laboratory-confirmed SARS-CoV-2 infection was diagnosed by real-time reverse transcriptase–polymerase chain reaction (RT-PCR) assay using a nasal/pharyngeal specimen during or prior to hospital admission. Sociodemographic and detailed clinical data of the patients, including comorbidities and history of influenza immunization, were recorded. Hospitalized patients with documented “do not intubate and/or do not resuscitate” orders and those who left the hospital against medical advice were excluded from the study. Patients who did not meet clinical endpoints for intubation were also excluded. Clinical outcomes, such as discharge, mortality, intubation, and comorbidities, were also obtained.
It is important to note that the patients who in this study were considered as vaccinated against influenza were the patients who received the vaccine in the 2019–2020 National Anti-influenza Vaccination Campaigns that began on 16 October 2019, which consisted of the application of one dose of trivalent anti-influenza vaccine type A and B [52].

2.2. Sample Size Calculation

The size of sample calculated for the study was 1712 patients, and it was obtained online (https://www.questionpro.com/sample-size-calculator/, accessed on 3 September 2022), using the formula proposed by Murray and Larry (2005) [53] with a confidence level of 95%, p = 0.5, a margin of error of ±2.3679%, and the population of the State of Zacatecas, which is 1,622,138 inhabitants.

2.3. Data Analysis

Descriptive statistics and chi-square tests were used to compare clinicopathological characteristics of patients by influenza vaccination status. Odds ratios (ORs) with 95% confidence intervals (CIs) were computed for the association between dichotomous influenza immunization and the outcomes under study (i.e., symptomatology and mortality). Subsequently, the Kaplan–Meier method was used to plot the survival curve according to influenza vaccination status and days of hospitalization by COVID-19. Multivariate logistic regression was also performed to identify the association between comorbidities, risk factors, and the role of influenza vaccination on mortality in patients hospitalized with COVID-19. Statistical analysis was performed in SPSS software (version 13.0, SPSS Inc., Chicago, IL, USA). p-values < 0.05 were considered statistically significant.

3. Results

In this study, 1712 patients were included. The age of the patients ranged from 20 to 86 years, with a mean age of 63.7 years 1–2; 978 (57.1%) were men and 734 (42.9%) were women. Almost 30% (29.7%) had received the influenza vaccine (trivalent influenza vaccine A and B), mostly men (60.7%). Of the 1203 patients without the influenza vaccine, 669 (55.6%) were male.
Symptoms reported by vaccinated patients included cough (100%), attack to the general state (89.9%), headache (83.4%), thoracic pain (77.9%), and fever (66.6%). Decreased ORs were seen in vaccinated patients for rhinorrhea (OR = 0.6; 95% CI: 0.4–0.8, p = 0.001), polypnea (OR = 0.4; 95% CI: 0.3–0.6, p < 0.001), cyanosis (OR = 0.6; 95% CI: 0.4–0.8, p < 0.001), anosmia (OR = 0.5; 95% CI: 0.4–0.7, p < 0.001), dysgeusia (OR = 0.4; 95% CI: 0.3–0.5, p < 0.001), fever (OR = 0.5; 95% CI: 0.4–0.7, p < 0.001), and arthralgias (OR = 0.6; 95% CI: 0.5–0.8, p < 0.001).
Respiratory symptoms such as cough, thoracic pain, and general symptoms, such as headache and chills, were present in a greater proportion of patients vaccinated when they were compared with non-influenza-vaccinated patients (p < 0.05; OR range: 1.1 to 2.4). Comorbidities such as T2DM and hypertension represented a high percentage in both the vaccinated (38.7% and 55.5%, respectively) and non-vaccinated (49.3% and 62.9%, respectively). Hypertension showed less risk of being present in patients vaccinated against influenza, and was 0.7 (95% CI: 0.5–0.9, p = 0.005) (Table 1).
For the survival analysis of patients hospitalized with COVID-19, both the data of patients vaccinated against influenza and those not vaccinated were considered, as well as the days spent in hospital. There was an average of 3.7 days of hospitalization in vaccinated patients versus 6.9 days of hospitalization in non-vaccinated patients, obtaining a statistically significant difference (p = 0.029) in the Long Rank test (Mantel–Cox) (Figure 2).
Using multivariate analysis, we observed that there was no association between the outcome of patients with COVID-19 and influenza vaccination status (OR = 0.9; 95% CI: 0.6–1.2, p = 0.657); however, critical condition, such as intubation, was associated with death in patients with COVID-19 (OR = 12.8; 95% CI: 7.0–20.5, p < 0.001), as well as other comorbidities such as T2DM (OR = 2.3; 95% CI: 1.7–3, p < 0.001), heart disease (OR = 5.1; 95% CI: 2.6–9.7], p < 0.001), obesity (OR = 9.5; 95% CI: 7–12.9, p < 0.001), and tobaccoism (OR = 2.4; 95% CI: 1.6–3.8, p < 0.001) (Table 2).

4. Discussion

Influenza vaccination is considered the most effective measure to prevent influenza and influenza-related complications, especially in high-risk populations. It has been reported that the mortality rate for COVID-19 appears to be higher than for seasonal influenza, with the caveat that both diseases primarily affect older adults (>65 years). This higher mortality rate from COVID-19 could be due to complications that develop depending on underlying comorbidities of the patients, population immunity, viral pathogenicity, and the immune system response of the patient. The aim of this study was to evaluate the possible protective effect of influenza vaccine on the occurrence of SARS-CoV-2 infection symptoms and the outcome in patients hospitalized due to COVID-19. According to our results, the application of the influenza vaccine influences a decrease in the presence of symptoms such as fever, diarrhea, myalgia, arthralgia, rhinorrhea, polypnea, cyanosis, and anosmia in patients infected with SARS-CoV-2. Other symptoms such as cough, chest pain, colds, headache, and general condition attack were more likely to occur in vaccinated patients compared to unvaccinated subjects; these results are in agreement with previous reports [54,55].
A retrospective cohort study in Michigan, USA, describes that patients who received an influenza vaccine tended to have more comorbidities than those in the unvaccinated group, including higher rates of chronic lung disease, congestive heart failure, T2DM, and high blood pressure. Compared to this study, we observed that patients with comorbidities such as T2DM, hypertension, heart disease, and COPD were less likely to be hospitalized for COVID-19 if they had received influenza vaccination compared to non-vaccinated patients. This could be explained by the fact that patients with pre-existing medical conditions often receive preventive therapies such as influenza vaccination [56].
It has been suggested that when analyzing the impact of influenza vaccination with COVID-19 risk factors for complications, they observed a reduced risk in patients with cardiovascular disease, T2DM, pulmonary disease, and chronic kidney disease [57]. In comparison, in the present report, we observed a decreased rate and risk of hospitalization in patients with T2DM, COPD, hypertension, and heart disease who were vaccinated against influenza. It was published in 2020 that patients with COVID-19 who received an inactivated trivalent influenza vaccine were more likely to survive and required less intensive hospital care than patients without influenza vaccination [10]. Data from this research suggest that patients vaccinated against influenza are more likely to leave the hospital due to improvement compared to patients who were not vaccinated against influenza. Additionally, Ragni et al. (2020) described a lower risk of hospitalization and death in patients with COVID-19 who had received influenza vaccine [51].
One possible explanation for the protective effect of influenza vaccination in some of the patients who did receive the dose is that unvaccinated individuals are at risk of persistent viral infections, which may lead to a decrease in T-cell counts that, in turn, affects the immune response to SARS-CoV-2 [58,59]. It is also known that influenza vaccination does not induce a strong virus-specific CD8 T-cell immune response compared with natural infection, and although this comparison may be a disadvantage of inactivated influenza vaccines, it is beneficial for eliminating SARS-CoV-2 infection, as vaccinated persons will have more T-cell diversity compared with persons who were naturally infected with influenza [60,61].
It is noteworthy that influenza virus alters the cytotoxic effect of natural killer (NK) cells and induces apoptosis, which ultimately alters host immune defense mechanisms against SARS-CoV-2 in the acute phase of the disease [62,63,64]. Patients who did not receive influenza vaccination have a higher proportion of influenza-specific resident memory T cells (TRM), which are highly proliferative and highly productive of inflammatory cytokines in the lungs [65,66], which is associated with an exaggerated severe ARDS inflammatory response seen in some patients with COVID-19 [67]. This immunological mechanism that explains the protective effects of influenza vaccine against COVID-19 is a process called trained immunity [68].
This immune response to viral pathogens is a fundamental feature of the adaptive immune system, leading to more rapid immune responses after subsequent reinfection [69]; these responses are most frequently directed to viral surface antigens, e.g., influenza hemagglutinin [70] and the SARS-CoV-2 spike protein [71]. Each antigen contains binding proteins for B- and T-cell receptors, termed epitopes [72]. Antibody responses to viral pathogens depend on B cells that “neutralize” the infection; most antibody responses are neutralizing antibodies, so their balance determines the efficacy of the response [73].
Influenza vaccine-induced trained immunity against SARS-CoV-2 induces the cytokine response at the onset of infection that is crucial for decreasing viral load and preventing systemic inflammation. The amplified IL-6 response activates acute-phase proteins, stimulates the development of effector T cells in conjunction with antibody production, forming the link between adaptive and innate immunity, leading to clearance of infection [74]. In contrast, anti-inflammatory cytokines such as IL-1Ra are necessary to counteract excessive inflammation; an increase in IL-6 production has been observed in parallel with IL-1Ra after stimulation with influenza vaccine, which contributes to maintaining a balance in the inflammatory state of patients [75]. It is also known that trained immunity is induced in NK cells, which suppress viral infections, through the production of IFN-γ, this production being after stimulation with influenza vaccine. There is a functional reprogramming of NK cells, which subsequently activate macrophages and promote pathogen clearance [76].
However, it should be noted that there are reports indicating that there was no beneficial effect of influenza vaccination on the risk of in-hospital mortality, indicating that vaccination did not change COVID-19-related morbidity and mortality [18]. Consistent with Conlon et al. (2021), who indicated that influenza-vaccinated patients were more likely to have a shorter hospital stay, in our study, the days of hospital stay were reduced in patients with influenza vaccination status [56]. Adjusting the analysis of this study, we observed that COVID-19-related deaths were not related to influenza vaccination status in patients, but were related to T2DM, heart disease, obesity, and smoking. Consistent with Conlon et al. (2021), who indicated that influenza-vaccinated patients were more likely to have a shorter hospital stay, in our study, the days of hospital stay were edited in patients with influenza vaccination status [56]. Adjusting the analysis of this study, we observed that COVID-19-related deaths were not related to influenza vaccination status in patients, but were related to T2DM, heart disease, obesity, and smoking. Pedote et al. (2021) also report finding no association between influenza vaccination and risk of death in patients with COVID-19; they also report that chronic diseases are the main risk factors for COVID-19-related hospitalization and death.
In this study, the comorbidities associated with death caused by COVID-19 complications are T2DM, heart disease, and obesity [77,78]. A study in Spain showed that mortality in patients with COVID-19 was associated with age and comorbidities according to the Charlson comorbidity index, and not vaccination status; they consider comorbidities to be significant independent predictors of mortality [79]. In this study, the comorbidities associated with death caused by COVID-19 complications were T2DM, heart disease, and obesity [77,78]. Mortality in patients with COVID-19 was associated with age and comorbidities according to the Charlson comorbidity index, and not vaccination status [79]; comorbidities were independent predictors of mortality [79].
In this investigation we report the influence of influenza vaccination on COVID-19, which allowed us to estimate the association between influenza vaccination and its relationship with the presence of symptoms, evolution, and outcome of patients with COVID-19. Although influenza vaccination has no impact on severe manifestations of COVID-19, it should be promoted as an essential public health preventive measure throughout the world’s population because, as Paget et al. (2020) point out, avoiding influenza infections can facilitate the differential diagnosis of COVID-19 and free up healthcare facilities to care for these patients [80]. In addition, influenza vaccination is critical in protecting older adults, with higher vaccination coverage among the elderly, healthcare workers, vulnerable people with chronic diseases, and workers in other essential services. It can also influence the health effects and social consequences of the COVID-19 pandemic [14].

5. Conclusions

The findings of this study suggest that influenza vaccination was associated with a decrease in the number of symptoms in patients hospitalized due to COVID-19, as well as a decrease in the number of patients hospitalized with comorbidities. The duration of hospitalization in vaccinated patients was less and the survival of these patients was significantly higher than that of unvaccinated patients. While influenza vaccination did not correlate with the outcome in patients with COVID-19, comorbidities such as T2DM, heart disease, obesity, and tobaccoism increased the risk of death due to COVID-19. These results can guide clinicians for proper prognostication and treatment planning of patients.

Author Contributions

Conceptualization, L.A.-C. and M.L.M.-F.; methodology, M.L.M.-F., J.R.G.-C. and A.G.-M.; formal analysis, M.L.M.-F., J.R.G.-C., A.G.-M., I.G.-V., I.P.R.-S. and I.D.-E.; investigation, A.M.-R.-E., F.E.M.-M., J.R.M.-T. and R.A.-E.; resources, M.L.M.-F., A.M.-R.-E., P.M.T.-O., I.G.-V., I.P.R.-S. and I.D.-E.; data curation, J.R.G.-C., M.L.M.-F. and A.G.-M.; writing—original draft preparation, J.R.G.-C., L.A.-C. and M.L.M.-F.; writing—review and editing, M.L.M.-F., J.R.G.-C. and L.A.-C.; visualization, L.A.-C. and M.L.M.-F.; supervision, M.L.M.-F. and L.A.-C.; project administration, M.L.M.-F.; funding acquisition, M.L.M.-F. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was revised and approved by the Ethics and Research Committee at the Zacatecas General Hospital Luz González Cosío (ID 02023/2019).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding authors [M.L.M.-F. and L.A.-C.].

Acknowledgments

The first author wants to thank the doctorate scholarships, with Scholarship Holder Number 15422 received by CONACYT through the Doctorado en Ciencias con Orientación en Medicina Molecular of Universidad Autónoma de Zacatecas.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef] [PubMed]
  2. Itelman, E.; Wasserstrum, Y.; Segev, A.; Avaky, C.; Negru, L.; Cohen, D.; Turpashvili, N.; Anani, S.; Zilber, E.; Lasman, N.; et al. Clinical Characterization of 162 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center. Isr. Med. Assoc. J. 2020, 22, 271–274. [Google Scholar] [PubMed]
  3. World Health Organization. Weekly Epidemiological Update on COVID-19. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-september-2023 (accessed on 4 October 2023).
  4. Bai, L.; Zhao, Y.; Dong, J.; Liang, S.; Guo, M.; Liu, X.; Wang, X.; Huang, Z.; Sun, X.; Zhang, Z.; et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021, 31, 395–403. [Google Scholar] [CrossRef] [PubMed]
  5. Nelson, M.I.; Tan, Y.; Ghedin, E.; Wentworth, D.E.; St George, K.; Edelman, L.; Beck, E.T.; Fan, J.; Lam, T.T.; Kumar, S.; et al. Phylogeography of the spring and fall waves of the H1N1/09 pandemic influenza virus in the United States. J. Virol. 2011, 85, 828–834. [Google Scholar] [CrossRef] [PubMed]
  6. Xiang, X.; Wang, Z.H.; Ye, L.L.; He, X.L.; Wei, X.S.; Ma, Y.L.; Li, H.; Chen, L.; Wang, X.R.; Zhou, Q. Co-infection of SARS-COV-2 and Influenza A Virus: A Case Series and Fast Review. Curr. Med. Sci. 2021, 41, 51–57. [Google Scholar] [CrossRef] [PubMed]
  7. Konala, V.M.; Adapa, S.; Gayam, V.; Naramala, S.; Daggubati, S.R.; Kammari, C.B.; Chenna, A. Co-infection with Influenza A and COVID-19. Eur. J. Case Rep. Intern. Med. 2020, 7, 001656. [Google Scholar] [CrossRef] [PubMed]
  8. Buchy, P.; Badur, S. Who and when to vaccinate against influenza. Int. J. Infect. Dis. 2020, 93, 375–387. [Google Scholar] [CrossRef] [PubMed]
  9. Sallam, M.; Ghazy, R.M.; Al-Salahat, K.; Al-Mahzoum, K.; Al Hadidi, N.M.; Eid, H.; Kareem, N.; Al-Ajlouni, E.; Batarseh, R.; Ababneh, N.A.; et al. The Role of Psychological Factors and Vaccine Conspiracy Beliefs in Influenza Vaccine Hesitancy and Uptake among Jordanian Healthcare Workers during the COVID-19 Pandemic. Vaccines 2022, 10, 1355. [Google Scholar] [CrossRef] [PubMed]
  10. Fink, G.; Orlova-Fink, N.; Schindler, T.; Grisi, S.; Ferrer, A.P.S.; Daubenberger, C.; Brentani, A. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ Evid. Based. Med. 2020, 26, 192–193. [Google Scholar] [CrossRef] [PubMed]
  11. Wolff, G.G. Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017–2018 influenza season. Vaccine 2020, 38, 350–354. [Google Scholar] [CrossRef]
  12. Kapoula, G.V.; Vennou, K.E.; Bagos, P.G. Influenza and Pneumococcal Vaccination and the Risk of COVID-19: A Systematic Review and Meta-Analysis. Diagnostics 2022, 12, 3086. [Google Scholar] [CrossRef] [PubMed]
  13. Del Riccio, M.; Lorini, C.; Bonaccorsi, G.; Paget, J.; Caini, S. The Association between Influenza Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and Death: A Systematic Review of the Literature. Int. J. Environ. Res. Public Health 2020, 17, 7870. [Google Scholar] [CrossRef] [PubMed]
  14. Cocco, P.; Meloni, F.; Coratza, A.; Schirru, D.; Campagna, M.; De Matteis, S. Vaccination against seasonal influenza and socio-economic and environmental factors as determinants of the geographic variation of COVID-19 incidence and mortality in the Italian elderly. Prev. Med. 2021, 143, 106351. [Google Scholar] [CrossRef] [PubMed]
  15. Amato, M.; Werba, J.P.; Frigerio, B.; Coggi, D.; Sansaro, D.; Ravani, A.; Ferrante, P.; Veglia, F.; Tremoli, E.; Baldassarre, D. Relationship between Influenza Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. Vaccines 2020, 8, 535. [Google Scholar] [CrossRef] [PubMed]
  16. Arokiaraj, M.C. Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality-Perspectives. Front. Public Health 2020, 8, 444. [Google Scholar] [CrossRef] [PubMed]
  17. Marin-Hernandez, D.; Schwartz, R.E.; Nixon, D.F. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. J. Med. Virol. 2021, 93, 64–65. [Google Scholar] [CrossRef] [PubMed]
  18. Martinez-Baz, I.; Trobajo-Sanmartin, C.; Arregui, I.; Navascues, A.; Adelantado, M.; Indurain, J.; Fresan, U.; Ezpeleta, C.; Castilla, J. Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers. Vaccines 2020, 8, 611. [Google Scholar] [CrossRef]
  19. de la Cruz Conty, M.L.; Encinas Pardilla, M.B.; Garcia Sanchez, M.; Gonzalez Rodriguez, L.; Muner-Hernando, M.L.; Royuela Vicente, A.; Pintado Recarte, P.; Martinez Varea, A.; Martinez Diago, C.; Cruz Melguizo, S.; et al. Impact of Recommended Maternal Vaccination Programs on the Clinical Presentation of SARS-CoV-2 Infection: A Prospective Observational Study. Vaccines 2021, 9, 31. [Google Scholar] [CrossRef] [PubMed]
  20. Kissling, E.; Hooiveld, M.; Brytting, M.; Vilcu, A.M.; de Lange, M.; Martinez-Baz, I.; Sigerson, D.; Enkirch, T.; Belhillil, S.; Meijer, A.; et al. Absence of association between 2019–20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020. Influenza Respir. Viruses 2021, 15, 429–438. [Google Scholar] [CrossRef]
  21. Padilla-Quirarte, H.O.; Lopez-Guerrero, D.V.; Gutierrez-Xicotencatl, L.; Esquivel-Guadarrama, F. Protective Antibodies Against Influenza Proteins. Front. Immunol. 2019, 10, 1677. [Google Scholar] [CrossRef]
  22. Netea, M.G.; Dominguez-Andres, J.; Barreiro, L.B.; Chavakis, T.; Divangahi, M.; Fuchs, E.; Joosten, L.A.B.; van der Meer, J.W.M.; Mhlanga, M.M.; Mulder, W.J.M.; et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 2020, 20, 375–388. [Google Scholar] [CrossRef] [PubMed]
  23. Pawlowski, C.; Puranik, A.; Bandi, H.; Venkatakrishnan, A.J.; Agarwal, V.; Kennedy, R.; O’Horo, J.C.; Gores, G.J.; Williams, A.W.; Halamka, J.; et al. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. Sci. Rep. 2021, 11, 4741. [Google Scholar] [CrossRef] [PubMed]
  24. Goh, K.J.; Choong, M.C.; Cheong, E.H.; Kalimuddin, S.; Duu Wen, S.; Phua, G.C.; Chan, K.S.; Haja Mohideen, S. Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from Coronavirus Disease 2019 (COVID-19) Infection. Ann. Acad. Med. Singap. 2020, 49, 108–118. [Google Scholar] [CrossRef] [PubMed]
  25. Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020, 8, 475–481. [Google Scholar] [CrossRef]
  26. Camporota, L.; Sanderson, B.; Dixon, A.; Vasques, F.; Jones, A.; Shankar-Hari, M. Outcomes in mechanically ventilated patients with hypoxaemic respiratory failure caused by COVID-19. Br. J. Anaesth. 2020, 125, e480–e483. [Google Scholar] [CrossRef]
  27. Abdallah, K.; Hamed, F.; Rahman, N.; Salam, S.; Mallat, J. Characteristics of critically ill patients infected with COVID-19 in Abu Dhabi, United Arab Emirates. Anaesth. Crit. Care Pain Med. 2020, 39, 483–485. [Google Scholar] [CrossRef]
  28. Suleyman, G.; Fadel, R.A.; Malette, K.M.; Hammond, C.; Abdulla, H.; Entz, A.; Demertzis, Z.; Hanna, Z.; Failla, A.; Dagher, C.; et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw. Open 2020, 3, e2012270. [Google Scholar] [CrossRef]
  29. Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F.X.; Chong, M.; Lee, M. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 2020, 323, 1612–1614. [Google Scholar] [CrossRef]
  30. Driggin, E.; Madhavan, M.V.; Bikdeli, B.; Chuich, T.; Laracy, J.; Biondi-Zoccai, G.; Brown, T.S.; Der Nigoghossian, C.; Zidar, D.A.; Haythe, J.; et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J. Am. Coll. Cardiol. 2020, 75, 2352–2371. [Google Scholar] [CrossRef]
  31. Kochi, A.N.; Tagliari, A.P.; Forleo, G.B.; Fassini, G.M.; Tondo, C. Cardiac and arrhythmic complications in patients with COVID-19. J. Cardiovasc. Electrophysiol. 2020, 31, 1003–1008. [Google Scholar] [CrossRef]
  32. Goha, A.; Mezue, K.; Edwards, P.; Nunura, F.; Baugh, D.; Madu, E. COVID-19 and the heart: An update for clinicians. Clin. Cardiol. 2020, 43, 1216–1222. [Google Scholar] [CrossRef] [PubMed]
  33. Dhakal, B.P.; Sweitzer, N.K.; Indik, J.H.; Acharya, D.; William, P. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. Heart Lung Circ. 2020, 29, 973–987. [Google Scholar] [CrossRef]
  34. Loungani, R.S.; Rehorn, M.R.; Newby, L.K.; Katz, J.N.; Klem, I.; Mentz, R.J.; Jones, W.S.; Vemulapalli, S.; Kelsey, A.M.; Blazing, M.A.; et al. A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. Am. Heart J. 2020, 225, 3–9. [Google Scholar] [CrossRef] [PubMed]
  35. Antony, S.J.; Almaghlouth, N.K.; Heydemann, E.L. Are coinfections with COVID-19 and influenza low or underreported? An observational study examining current published literature including three new unpublished cases. J. Med. Virol. 2020, 92, 2489–2497. [Google Scholar] [CrossRef]
  36. Osterholm, M.T.; Kelley, N.S.; Sommer, A.; Belongia, E.A. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12, 36–44. [Google Scholar] [CrossRef]
  37. Grohskopf, L.A.; Alyanak, E.; Broder, K.R.; Walter, E.B.; Fry, A.M.; Jernigan, D.B. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2019–2020 Influenza Season. MMWR Recomm. Rep. 2019, 68, 1–21. [Google Scholar] [CrossRef]
  38. Grandhi, G.R.; Mszar, R.; Vahidy, F.; Valero-Elizondo, J.; Blankstein, R.; Blaha, M.J.; Virani, S.S.; Andrieni, J.D.; Omer, S.B.; Nasir, K. Sociodemographic Disparities in Influenza Vaccination Among Adults With Atherosclerotic Cardiovascular Disease in the United States. JAMA Cardiol. 2021, 6, 87–91. [Google Scholar] [CrossRef]
  39. Keilman, L.J. Seasonal Influenza (Flu). Nurs. Clin. N. Am. 2019, 54, 227–243. [Google Scholar] [CrossRef] [PubMed]
  40. Ashur, C.; Norton, E.; Farhat, L.; Conlon, A.; Willer, C.; Froehlich, J.B.; Pinsky, D.J.; Kim, K.M.; Fukuhara, S.; Deeb, M.G.; et al. Higher admission rates and in-hospital mortality for acute type A aortic dissection during Influenza season: A single center experience. Sci. Rep. 2020, 10, 4723. [Google Scholar] [CrossRef]
  41. Kodama, M. Influenza myocarditis. Circ. J. 2010, 74, 2060–2061. [Google Scholar] [CrossRef]
  42. Madjid, M.; Naghavi, M.; Litovsky, S.; Casscells, S.W. Influenza and cardiovascular disease: A new opportunity for prevention and the need for further studies. Circulation 2003, 108, 2730–2736. [Google Scholar] [CrossRef] [PubMed]
  43. Rollins, G. Study confirms multiple benefits of influenza vaccination. Rep. Med. Guidel. Outcomes Res. 2003, 14, 7–9. [Google Scholar] [PubMed]
  44. Luce, B.R.; Nichol, K.L.; Belshe, R.B.; Frick, K.D.; Li, S.X.; Boscoe, A.; Rousculp, M.D.; Mahadevia, P.J. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine 2008, 26, 2841–2848. [Google Scholar] [CrossRef] [PubMed]
  45. Udell, J.A.; Zawi, R.; Bhatt, D.L.; Keshtkar-Jahromi, M.; Gaughran, F.; Phrommintikul, A.; Ciszewski, A.; Vakili, H.; Hoffman, E.B.; Farkouh, M.E.; et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: A meta-analysis. JAMA 2013, 310, 1711–1720. [Google Scholar] [CrossRef] [PubMed]
  46. Battistoni, A.; Volpe, M. Flu Vaccination as a Key Prevention Recommendation for Patients at High Cardiovascular Risk: The Next Season’s Scenario. High Blood Press Cardiovasc. Prev. 2022, 29, 405–407. [Google Scholar] [CrossRef] [PubMed]
  47. Behrouzi, B.; Bhatt, D.L.; Cannon, C.P.; Vardeny, O.; Lee, D.S.; Solomon, S.D.; Udell, J.A. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Netw. Open 2022, 5, e228873. [Google Scholar] [CrossRef]
  48. Karacaer, C.; Yaylaci, S.; Demirci, T.; Cekic, D.; Suner, K.O.; Cokluk, E.; Varim, C. Association of mortality and endothelial dysfunction with serum ADMA level in COVID-19 patients. Pak. J. Med. Sci. 2022, 38, 1808–1815. [Google Scholar] [CrossRef]
  49. Smith, S.C., Jr.; Allen, J.; Blair, S.N.; Bonow, R.O.; Brass, L.M.; Fonarow, G.C.; Grundy, S.M.; Hiratzka, L.; Jones, D.; Krumholz, H.M.; et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113, 2363–2372. [Google Scholar] [CrossRef]
  50. O’Connor, E.; Teh, J.; Kamat, A.M.; Lawrentschuk, N. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19—What’s old is new again? Future Oncol. 2020, 16, 1323–1325. [Google Scholar] [CrossRef]
  51. Ragni, P.; Marino, M.; Formisano, D.; Bisaccia, E.; Scaltriti, S.; Bedeschi, E.; Grilli, R. Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes. Vaccines 2020, 8, 675. [Google Scholar] [CrossRef]
  52. México, G.d. Campaña Nacional de Vacunación Anti-Influenza 2019–2020. 2019. Available online: https://www.gob.mx/salud/prensa/291-inicia-sector-salud-campana-nacional-de-vacunacion-anti-influenza?idiom=es (accessed on 4 October 2023).
  53. Baldwin, S.A.; Murray, D.M.; Shadish, W.R. Empirically supported treatments or type I errors? Problems with the analysis of data from group-administered treatments. J. Consult. Clin. Psychol. 2005, 73, 924–935. [Google Scholar] [CrossRef]
  54. Wang, Q.; Yue, N.; Zheng, M.; Wang, D.; Duan, C.; Yu, X.; Zhang, X.; Bao, C.; Jin, H. Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis. Vaccine 2018, 36, 7262–7269. [Google Scholar] [CrossRef]
  55. Piroth, L.; Cottenet, J.; Mariet, A.S.; Bonniaud, P.; Blot, M.; Tubert-Bitter, P.; Quantin, C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: A nationwide, population-based retrospective cohort study. Lancet Respir. Med. 2021, 9, 251–259. [Google Scholar] [CrossRef]
  56. Conlon, A.; Ashur, C.; Washer, L.; Eagle, K.A.; Hofmann Bowman, M.A. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am. J. Infect. Control. 2021, 49, 694–700. [Google Scholar] [CrossRef] [PubMed]
  57. Vila-Corcoles, A.; Ochoa-Gondar, O.; Satue-Gracia, E.M.; Torrente-Fraga, C.; Gomez-Bertomeu, F.; Vila-Rovira, A.; Hospital-Guardiola, I.; de Diego-Cabanes, C.; Bejarano-Romero, F.; Basora-Gallisa, J. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: A population-based cohort study in Tarragona, Spain. BMJ Open 2020, 10, e041577. [Google Scholar] [CrossRef]
  58. Lambert, N.D.; Ovsyannikova, I.G.; Pankratz, V.S.; Jacobson, R.M.; Poland, G.A. Understanding the immune response to seasonal influenza vaccination in older adults: A systems biology approach. Expert Rev. Vaccines 2012, 11, 985–994. [Google Scholar] [CrossRef]
  59. Channappanavar, R.; Fehr, A.R.; Vijay, R.; Mack, M.; Zhao, J.; Meyerholz, D.K.; Perlman, S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 2016, 19, 181–193. [Google Scholar] [CrossRef]
  60. Grant, E.J.; Josephs, T.M.; Loh, L.; Clemens, E.B.; Sant, S.; Bharadwaj, M.; Chen, W.; Rossjohn, J.; Gras, S.; Kedzierska, K. Broad CD8(+) T cell cross-recognition of distinct influenza A strains in humans. Nat. Commun. 2018, 9, 5427. [Google Scholar] [CrossRef]
  61. McElhaney, J.E.; Verschoor, C.P.; Andrew, M.K.; Haynes, L.; Kuchel, G.A.; Pawelec, G. The immune response to influenza in older humans: Beyond immune senescence. Immun. Ageing 2020, 17, 10. [Google Scholar] [CrossRef]
  62. Mao, H.; Tu, W.; Liu, Y.; Qin, G.; Zheng, J.; Chan, P.L.; Lam, K.T.; Peiris, J.S.; Lau, Y.L. Inhibition of human natural killer cell activity by influenza virions and hemagglutinin. J. Virol. 2010, 84, 4148–4157. [Google Scholar] [CrossRef]
  63. Denney, L.; Aitken, C.; Li, C.K.; Wilson-Davies, E.; Kok, W.L.; Clelland, C.; Rooney, K.; Young, D.; Dong, T.; McMichael, A.J.; et al. Reduction of natural killer but not effector CD8 T lymphocytes in three consecutive cases of severe/lethal H1N1/09 influenza A virus infection. PLoS ONE 2010, 5, e10675. [Google Scholar] [CrossRef] [PubMed]
  64. Mao, H.; Tu, W.; Qin, G.; Law, H.K.; Sia, S.F.; Chan, P.L.; Liu, Y.; Lam, K.T.; Zheng, J.; Peiris, M.; et al. Influenza virus directly infects human natural killer cells and induces cell apoptosis. J. Virol. 2009, 83, 9215–9222. [Google Scholar] [CrossRef] [PubMed]
  65. Purwar, R.; Campbell, J.; Murphy, G.; Richards, W.G.; Clark, R.A.; Kupper, T.S. Resident memory T cells (T(RM)) are abundant in human lung: Diversity, function, and antigen specificity. PLoS ONE 2011, 6, e16245. [Google Scholar] [CrossRef] [PubMed]
  66. Pizzolla, A.; Nguyen, T.H.; Sant, S.; Jaffar, J.; Loudovaris, T.; Mannering, S.I.; Thomas, P.G.; Westall, G.P.; Kedzierska, K.; Wakim, L.M. Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. J. Clin. Investig. 2018, 128, 721–733. [Google Scholar] [CrossRef] [PubMed]
  67. Henderson, L.A.; Canna, S.W.; Schulert, G.S.; Volpi, S.; Lee, P.Y.; Kernan, K.F.; Caricchio, R.; Mahmud, S.; Hazen, M.M.; Halyabar, O.; et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020, 72, 1059–1063. [Google Scholar] [CrossRef] [PubMed]
  68. Lee, C.H.; Pinho, M.P.; Buckley, P.R.; Woodhouse, I.B.; Ogg, G.; Simmons, A.; Napolitani, G.; Koohy, H. Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains. Front. Immunol. 2020, 11, 579480. [Google Scholar] [CrossRef] [PubMed]
  69. Dorner, T.; Radbruch, A. Antibodies and B cell memory in viral immunity. Immunity 2007, 27, 384–392. [Google Scholar] [CrossRef] [PubMed]
  70. Sangster, M.Y.; Nguyen, P.Q.T.; Topham, D.J. Role of Memory B Cells in Hemagglutinin-Specific Antibody Production Following Human Influenza A Virus Infection. Pathogens 2019, 8, 167. [Google Scholar] [CrossRef] [PubMed]
  71. Rodda, L.B.; Morawski, P.A.; Pruner, K.B.; Fahning, M.L.; Howard, C.A.; Franko, N.; Logue, J.; Eggenberger, J.; Stokes, C.; Golez, I.; et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell 2022, 185, 1588–1601.e1514. [Google Scholar] [CrossRef]
  72. Ahmed, S.F.; Quadeer, A.A.; McKay, M.R. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 2020, 12, 254. [Google Scholar] [CrossRef]
  73. Banerjee, A.; Santra, D.; Maiti, S. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID-19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development. J. Transl. Med. 2020, 18, 281. [Google Scholar] [CrossRef] [PubMed]
  74. Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014, 6, a016295. [Google Scholar] [CrossRef] [PubMed]
  75. Moorlag, S.; Roring, R.J.; Joosten, L.A.B.; Netea, M.G. The role of the interleukin-1 family in trained immunity. Immunol. Rev. 2018, 281, 28–39. [Google Scholar] [CrossRef] [PubMed]
  76. Kleinnijenhuis, J.; Quintin, J.; Preijers, F.; Joosten, L.A.; Jacobs, C.; Xavier, R.J.; van der Meer, J.W.; van Crevel, R.; Netea, M.G. BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin. Immunol. 2014, 155, 213–219. [Google Scholar] [CrossRef] [PubMed]
  77. Pedote, P.D.; Termite, S.; Gigliobianco, A.; Lopalco, P.L.; Bianchi, F.P. Influenza Vaccination and Health Outcomes in COVID-19 Patients: A Retrospective Cohort Study. Vaccines 2021, 9, 358. [Google Scholar] [CrossRef] [PubMed]
  78. Candelli, M.; Pignataro, G.; Torelli, E.; Gulli, A.; Nista, E.C.; Petrucci, M.; Saviano, A.; Marchesini, D.; Covino, M.; Ojetti, V.; et al. Effect of influenza vaccine on COVID-19 mortality: A retrospective study. Intern. Emerg. Med. 2021, 16, 1849–1855. [Google Scholar] [CrossRef]
  79. Fernandez Ibanez, J.M.; Morales Ballesteros, M.D.C.; Fernandez Anguita, M.J.; Galindo Andugar, M.A.; Arias Arias, A.; Barbera-Farre, J.R. Influence of influenza vaccine and comorbidity on the evolution of hospitalized COVID-19 patients small star, filled. Med. Clin. (Engl. Ed.) 2022, 158, 603–607. [Google Scholar] [CrossRef]
  80. Paget, J.; Caini, S.; Cowling, B.; Esposito, S.; Falsey, A.R.; Gentile, A.; Kyncl, J.; MacIntyre, C.; Pitman, R.; Lina, B. The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. Vaccine 2020, 38, 6485–6486. [Google Scholar] [CrossRef]
Vaccines 12 00765 g001
Figure 1. Production of anti-influenza antibodies. The generation of anti-influenza antibodies is generated prophylactically through the application of the influenza vaccine. Antibody formation begins with the presentation of antigens (components of the influenza virus) by dendritic cells and macrophages to naive CD4 lymphocytes, thereby generating activation of B and T lymphocytes. The activated B lymphocytes begin to produce antibodies on their surface, which undergo a maturation process, until finally, the plasma cells generate large quantities of mature antibodies specific for the identification and elimination of the influenza virus [21].
Figure 1. Production of anti-influenza antibodies. The generation of anti-influenza antibodies is generated prophylactically through the application of the influenza vaccine. Antibody formation begins with the presentation of antigens (components of the influenza virus) by dendritic cells and macrophages to naive CD4 lymphocytes, thereby generating activation of B and T lymphocytes. The activated B lymphocytes begin to produce antibodies on their surface, which undergo a maturation process, until finally, the plasma cells generate large quantities of mature antibodies specific for the identification and elimination of the influenza virus [21].
Vaccines 12 00765 g001
Vaccines 12 00765 g002
Figure 2. Survival analysis. Estimated Kaplan–Meier survival curve by influenza vaccination status (vaccinated patients: 509; unvaccinated patients: 1203) and days of hospitalization (vaccinated patients: 3.7 days on average; unvaccinated patients: 6.9 days on average) by COVID-19.
Figure 2. Survival analysis. Estimated Kaplan–Meier survival curve by influenza vaccination status (vaccinated patients: 509; unvaccinated patients: 1203) and days of hospitalization (vaccinated patients: 3.7 days on average; unvaccinated patients: 6.9 days on average) by COVID-19.
Vaccines 12 00765 g002
Table 1. General characteristics of study population. Table displays the comparison of clinicopathological findings in hospitalized patients with COVID-19 with and without influenza vaccine.
Table 1. General characteristics of study population. Table displays the comparison of clinicopathological findings in hospitalized patients with COVID-19 with and without influenza vaccine.
VariablesPopulation with Influenza Vaccine
n = 509 (%)		Population without
Influenza Vaccine
n = 1203 (%)		Odds Ratio
(95% CI)		p-Value
Sex 1.2 (0.7–2.0)0.05
M309 (60.7)669 (55.6)
F200 (39.2)534 (44.3)
Intubated36 (7)131 (10.8)0.6 (0.4–0.9)0.013
Fever339 (66.6)929 (77.2)0.5 (0.4–0.7)<0.001
Cough 509 (100)1022 (84.9)1.7 (1.1–2.7)<0.001
Odymphagia226 (44.4)494 (41)1.1 (0.9–1.4)0.201
Irritability28 (5.5)72 (5.9)0.9 (0.5–1.4)0.696
Diarrhea56 (11)252 (20.9)0.4 (0.3–0.6)<0.001
Thoracic Pain397 (77.9)778 (64.6)1.9 (1.5–2.4)<0.001
Chills283 (55.5)528 (43.8)1.6 (1.2–1.9)<0.001
Headache425 (83.4)931 (77.3)1.4 (1.1–1.9)0.004
Myalgia282 (55.4)771 (64)0.6 (0.5–0.8)0.001
Arthralgia282 (55.4)771 (64)0.6 (0.5–0.8)0.001
Attack to the general state453 (88.9)1002 (83.2)1.6 (1.1–2.2)0.003
Rhinorrhea86 (16.8)290 (24.1)0.6 (0.4–0.8)0.001
Polypnea256 (50.2)810 (67.3)0.4 (0.3–0.6)<0.001
Vomiting56 (11)108 (8.9)1.2 (0.8–1.7)0.193
Abdominal Pain84 (16.5)184 (15.2)1.0 (0.8–1.4)0.530
Cyanosis115 (22.5)380 (31.5)0.6 (0.4–0.8)<0.001
Anosmia140 (27.5)478 (39.7)0.5 (0.4–0.7)<0.001
Dysgeusia112 (22)462 (38.4)0.4 (0.3–0.5)<0.001
T2DM *197 (38.7)594 (49.3)0.6 (0.5–0.8)<0.001
COPD †28 (5.5)126 (10.4)0.4 (0.3–0.7)0.001
Asthma29 (5.6)48 (3.9)1.4 (0.9–2.3)0.119
Immunosuppression58 (11.3)110 (9.1)1.2 (0.9–1.7)0.152
Arterial Hypertension283 (55.5)757 (62.9)0.7 (0.5–0.9)0.005
Heart Disease28 (5.5)72 (5.9)0.9 (0.5–1.4)0.696
Obesity285 (55.9)615 (51.1)1.2 (0.9–1.4)0.065
Tobaccoism56 (11)169 (14)0.7 (0.5–1.0)0.088
Antiviral Treatment28 (5.5)92 (7.6)0.7 (0.4–1.0)0.112
* T2DM: type 2 diabetes mellitus; † COPD: chronic obstructive pulmonary disease.
Table 2. Multivariate analysis. Multivariate logistic regression analysis to evaluate the relationships between variables associated with the outcome of COVID-19 in hospitalized patients.
Table 2. Multivariate analysis. Multivariate logistic regression analysis to evaluate the relationships between variables associated with the outcome of COVID-19 in hospitalized patients.
VariableOutcomeCrude
Odds Ratio
(95% CI)		p-ValueAdjusted
Odds Ratio
(95% CI)		p-Value
Death
n = 582 (%)		Survivors
n = 1130 (%)
Vaccinated196 (33.6)291 (25.7)1.5 (1.1–1.8)0.0010.9 (0.6–1.2)0.657
Non Vaccinated386 (66.3)839 (74.2)
Intubated139 (23.8)28 (2.4)1.0 (0.6–1.5)0.0112.8 (7.9–20.5)<0.001
T2DM *281 (48.2)421 (37.2)1.8 (1.3–2.3)<0.0012.3 (1.7–3)<0.001
COPD †59 (10.1)49 (4.3)1.6 (0.1–2.6)0.0741.4 (0.9–2.4)0.109
Asthma30 (5.1)43 (3.8)0.6 (0.3–0.9)0.1280.6 (0.3–1.1)0.149
Immunosuppression62 (10.6)47 (4.1)0.9 (0.6–1.4)0.7061.2 (0.7–2.1)0.366
Arterial Hypertension332 (57)613 (54.2)1.1 (0.8–1.4)0.0020.7 (0.6–1.0)0.097
Heart Disease47 (8)20 (1.7)1.2 (1.1–1.2)0.035.1 (2.6–9.7)<0.001
Obesity302 (51.8)122 (10.7)1.6 (1.2–2.1)<0.0019.5 (7–12.9)<0.001
Tobaccoism83 (14.2)73 (6.4)1.2 (0.6–1.9)0.0012.4 (1.6–3.8)<0.001
* T2DM: type 2 diabetes mellitus. † COPD: chronic obstructive pulmonary disease.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gutierrez-Camacho, J.R.; Avila-Carrasco, L.; Gamón-Madrid, A.; Muñoz-Torres, J.R.; Murillo-Ruiz-Esparza, A.; Garza-Veloz, I.; Trejo-Ortiz, P.M.; Mollinedo-Montaño, F.E.; Araujo-Espino, R.; Rodriguez-Sanchez, I.P.; et al. Evaluation of the Effect of Influenza Vaccine on the Development of Symptoms in SARS-CoV-2 Infection and Outcome in Patients Hospitalized due to COVID-19. Vaccines 2024, 12, 765. https://doi.org/10.3390/vaccines12070765

AMA Style

Gutierrez-Camacho JR, Avila-Carrasco L, Gamón-Madrid A, Muñoz-Torres JR, Murillo-Ruiz-Esparza A, Garza-Veloz I, Trejo-Ortiz PM, Mollinedo-Montaño FE, Araujo-Espino R, Rodriguez-Sanchez IP, et al. Evaluation of the Effect of Influenza Vaccine on the Development of Symptoms in SARS-CoV-2 Infection and Outcome in Patients Hospitalized due to COVID-19. Vaccines. 2024; 12(7):765. https://doi.org/10.3390/vaccines12070765

Chicago/Turabian Style

Gutierrez-Camacho, Jose Roberto, Lorena Avila-Carrasco, Araceli Gamón-Madrid, Jose Ramon Muñoz-Torres, Alberto Murillo-Ruiz-Esparza, Idalia Garza-Veloz, Perla M. Trejo-Ortiz, Fabiana E. Mollinedo-Montaño, Roxana Araujo-Espino, Iram P. Rodriguez-Sanchez, and et al. 2024. "Evaluation of the Effect of Influenza Vaccine on the Development of Symptoms in SARS-CoV-2 Infection and Outcome in Patients Hospitalized due to COVID-19" Vaccines 12, no. 7: 765. https://doi.org/10.3390/vaccines12070765

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop